Edition:
United States

Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

66.98USD
4:00pm EDT
Change (% chg)

$0.38 (+0.57%)
Prev Close
$66.60
Open
$65.21
Day's High
$67.94
Day's Low
$65.21
Volume
31,787
Avg. Vol
39,461
52-wk High
$76.29
52-wk Low
$21.95

Chart for

About

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone... (more)

Overall

Beta: 0.63
Market Cap(Mil.): $2,766.40
Shares Outstanding(Mil.): 41.58
Dividend: --
Yield (%): --

Financials

  ASND.OQ Industry Sector
P/E (TTM): -- 241.68 34.14
EPS (TTM): -4.62 -- --
ROI: -55.80 -5.91 13.17
ROE: -55.80 -7.75 15.14

BRIEF-Ascendis Pharma Announces Dosing Of First Subjects In Phase 1 Trial Of Transcon CNP

* ASCENDIS PHARMA A/S ANNOUNCES DOSING OF FIRST SUBJECTS IN PHASE 1 TRIAL OF TRANSCON CNP

May 08 2018

BRIEF-Ascendis Pharma Reports Full Year 2017 Financial Results

* ASCENDIS PHARMA A/S REPORTS FULL YEAR 2017 FINANCIAL RESULTS

Mar 28 2018

BRIEF-Ascendis Pharma prices 3.9 mln American Depositary Shares At $57 Per ADS

* ASCENDIS PHARMA A/S ANNOUNCES PRICING OF PUBLIC OFFERING OF ADSS

Feb 21 2018

BRIEF-Ascendis Pharma A/S Announces Proposed Public Offering Of ADSS

* ASCENDIS PHARMA A/S ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS

Feb 20 2018

BRIEF-Ascendis Pharma Says Completed Target Enrollment In Phase 3 Trial Of Pediatric Growth Hormone Deficiency Treatment

* ASCENDIS PHARMA ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN PHASE 3 TRIAL OF TRANSCON GROWTH HORMONE FOR PEDIATRIC GROWTH HORMONE DEFICIENCY

Jan 03 2018

BRIEF-Ascendis Pharma Initiates Submissions In Australia To Enter Study With Transcon CNP

* ASCENDIS PHARMA SAYS ON DEC 20, INITIATED REGULATORY SUBMISSIONS IN AUSTRALIA TO ENTER INTO FIRST HUMAN CLINICAL STUDY WITH TRANSCON CNP - SEC FILING Source text : (http://bit.ly/2BTTLso) Further company coverage:

Dec 20 2017

Earnings vs. Estimates